AIMA
ZBH icon

Ables Iannone Moore & Associates’s Zimmer Biomet ZBH Stock Holding History

Ables Iannone Moore & Associates’s Portfolio ZBH Stock Details ZBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-250
Closed -$30.4K – 301
2023
Q4 		$30.4K Buy
+250
New +$27.9K 0.02% 119

Other funds holding ZBH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ables Iannone Moore & Associates's ZBH Position: Q1 2024 in Review

Ables Iannone Moore & Associates sold out of Zimmer Biomet (ZBH) in Q1 2024, closing a stake of 250 shares — an estimated $30.4K sold.

Ables Iannone Moore & Associates first reported a position in ZBH in Q4 2023 and held it in 1 quarter. The position peaked at $30.4K in Q4 2023. 1,011 funds tracked by Wall St. Rank hold ZBH as of Q1 2024.

  • Ables Iannone Moore & Associates reported no remaining Zimmer Biomet position as of Q1 2024 after selling out during the quarter.
  • Ables Iannone Moore & Associates sold 250 Zimmer Biomet shares in Q1 2024, an estimated $30.4K.
  • Ables Iannone Moore & Associates first reported a position in Zimmer Biomet in Q4 2023 and held it in 1 quarter.
  • Ables Iannone Moore & Associates's Zimmer Biomet position peaked at $30.4K in Q4 2023.
  • 1,011 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2024.

Based on Ables Iannone Moore & Associates's 13F filing for Q1 2024, filed 30 Apr 2024.